DTP Communications

  • Letter to prescribers

Mpox letter to DTP prescribers

  • Resource for Providers

BC-CfE Resources for Providers (Poster)

  • Notification of Initiative Launch

Doxycycline for Bacterial STI Prevention

Click here to link to information about this initiative

  • Considerations for the Prescriber

Cabotegravir and Rilpivirine Extended-Release Injectable Suspensions (Cabenuva(R))

Cabenuva(R) Recommendations (May 2024)
Cabenuva(R) Request Form (Jan 2025)
Considerations for the Client (May 2023)
  • Formulary Addition

Doravirine (Pifeltro(R)) and Doravirine-lamivudine-tenofovir disoproxil fumarate (Delstrigo(R))

  • Notice to Prescribers

Repeat Fill Authorization Permitted on BC-CfE Antiretroviral Prescriptions for the Treatment of HIV Infection

  • Notice to Prescribers

Updates to BC-CfE HIV Drug Treatment and Prevention Programs

  • Formulary Addition: Dolutegravir-lamivudine (Dovato®)
  • Resumption of routine HIV plasma viral load testing
  • Updates to BC-CfE Guidance Documents
  • Guidance document

Guideline for Antiretroviral Therapy (ART) Regimens for Initial Therapy and for Switching ART in Virologically Stable Suppressed Adults

  • Notice

BC Ministry of Health Directive to Include Antiretrovirals on PharmaNet

  • Notice to Prescribers

BC-CfE AND COVID-19: HIV Treatment and Prevention Programs Update

Scroll to Top

The British Columbia Centre for Excellence in HIV/AIDS Laboratory has discontinued gp-41 resistance testing as T-20 (enfuvirtide/Fuzeon) is no longer available in Canada as of March 31, 2025

Start typing and press enter to search